Dalian Medical University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Dalian China (1947)

Organization Overview

First Clinical Trial
2006
NCT01285219
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

14.The First Affiliated Hospital of Dalian Medical University | Dalian Children's Hospital | Dalian Medical University | Dalian Municipal Central Hospital | Dalian municipal central hospital affiliated of dalian medical university | Dalian University | Dalian University affiliated Zhongshan Hospital | First Hospital of Dalian Medical University | Liaoning Cancer Hospital & Institute | Liaoning thrombus treatment center of integrated chinese and western medicine | Liaoning Tumor Hospital & Institute | The 1st Affiliated Hospital, Dalian Medical Unversity | The Affiliated Zhongshan Hospital of Dalian University | The First Affiliated Hospital of Dalian Medical University | The Second Affiliated Hospital of Dalian Medical University | Wuhan Leishenshan Hospital | Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University | Xiaonan Cui | Zhang Rui

Active Ingredients

Drugs in Phase 4 Trials (39)

99mtc mdp (1 trial)

acetylsalicylic acid (aspirin) (2 trials)

aclarubicin (1 trial)

amiodarone (cordarone) (1 trial)

amoxicillin (1 trial)

atorvastatin (lipitor) (2 trials)

benidipine (coniel) (1 trial)

bismuth (1 trial)

bivalirudin (angiomax) (2 trials)

chidamide (2 trials)

cinobufacin (1 trial)

cinobufacini (1 trial)

clarithromycin (biaxin) (1 trial)

clopidogrel (plavix) (2 trials)

cytarabine (cytosar-u) (2 trials)

daunorubicin (cerubidine) (1 trial)

decitabine (dacogen) (1 trial)

dexamethasone (1 trial)

digoxin (lanoxin) (1 trial)

eltrombopag (promacta) (2 trials)

esomeprazole (nexium) (1 trial)

fosinopril (monopril) (1 trial)

fulvestrant (faslodex) (4 trials)

heparin (liquaemin) (3 trials)

huaiqihuang (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

ixazomib (ninlaro) (1 trial)

methylprednisolone (medrol) (1 trial)

metoprolol (lopressor) (2 trials)

mitoxantrone (novantrone) (1 trial)

pomalidomide (pomalyst) (1 trial)

Raltitrexed (Tomudex) (3 trials)

rosuvastatin (crestor) (2 trials)

somatropin (protropin) (1 trial)

thrombopoietin (6 trials)

ticagrelor (brilinta) (2 trials)

tongfusan (1 trial)

valsartan (diovan) (1 trial)

vonoprazan (Voquezna) (1 trial)

Drugs in Phase 3 Trials (45)

131i-lipiodol (Lipiodol) (1 trial)

capecitabine (xeloda) (6 trials)

cisplatin (platinol) (7 trials)

cladribine (leustatin) (1 trial)

cyclophosphamide (cytoxan) (4 trials)

docetaxel (taxotere) (3 trials)

doxorubicin (Doxil) (3 trials)

epirubicin (ellence) (3 trials)

erlotinib (tarceva) (2 trials)

etoposide (vepesid) (2 trials)

ferric citrate (AURYXIA) (1 trial)

Filgrastim (neupogen) (1 trial)

fluorouracil (efudex) (3 trials)

follitropin alfa (Gonal-F) (1 trial)

ganoderma lucidum spore (2 trials)

gefitinib (iressa) (3 trials)

gelatin (1 trial)

gemcitabine (gemzar) (3 trials)

irinotecan (Camptosar) (8 trials)

lenalidomide (revlimid) (2 trials)

leucovorin (2 trials)

nedaplatin (1 trial)

neuregulin (1 trial)

norepinephrine (levophed) (2 trials)

paclitaxel (taxol) (4 trials)

palonosetron (aloxi) (1 trial)

pembrolizumab (keytruda) (1 trial)

phenylephrine (Prefrin) (2 trials)

prednisone (meticorten) (3 trials)

qingyi (1 trial)

rasagiline (azilect) (1 trial)

rc48-adc (1 trial)

rituximab (rituxan) (5 trials)

sargramostim (leukine) (1 trial)

semustine (1 trial)

sevelamer (renagel) (1 trial)

sodium chloride (1 trial)

somatostatin (1 trial)

thalidomide (Thalomid) (2 trials)

urea (7 trials)

vincristine (oncovin) (3 trials)

vinorelbine (navelbine) (3 trials)

xelox (1 trial)

yinhu qingwen (1 trial)

zanubrutinib (Brukinsa) (2 trials)

Drugs in Phase 2 Trials (29)

ak105 (1 trial)

anlotinib (4 trials)

bat4406f (1 trial)

bevacizumab (avastin) (5 trials)

c-117 (1 trial)

carboplatin (paraplatin) (2 trials)

cd7 car-t cell (1 trial)

dalpiciclib (2 trials)

diacerein (1 trial)

duloxetine (Cymbalta) (1 trial)

endostatin (endostar) (2 trials)

ensartinib (1 trial)

fluzoparib (2 trials)

icotinib (Conmana) (2 trials)

ifosfamide (ifex) (1 trial)

lapatinib (tykerb) (4 trials)

Methylomonas (1 trial)

orelabrutinib (1 trial)

oseltamivir (tamiflu) (1 trial)

oxaliplatin (eloxatin) (5 trials)

pegaspargase (oncaspar) (1 trial)

pemetrexed (alimta) (1 trial)

regorafenib (stivarga) (2 trials)

sintilimab (3 trials)

sitagliptin (januvia) (1 trial)

sorafenib (nexavar) (1 trial)

tgrx-326 (1 trial)

tislelizumab (1 trial)

ziying (1 trial)

Drugs in Phase 1 Trials (4)

cpg-oligonucleotide (1 trial)

cytokine induced killer cells (1 trial)

trimetazidine (1 trial)

yanxinshi (1 trial)

Drugs in Other Trials (17)

acitretin (soriatane) (1 trial)

autologous hematopoietic stem cells (1 trial)

dapagliflozin (farxiga) (1 trial)

dextrose (1 trial)

esketamine (spravato) (1 trial)

febuxostat (uloric) (1 trial)

gabapentin (neurontin) (1 trial)

huangqi guizhi wuwu (1 trial)

linaclotide (linzess) (1 trial)

maltodextrin (1 trial)

paeony glucosides (1 trial)

peripheral blood lymphocytes (1 trial)

polyethylene glycol (1 trial)

pregabalin (lyrica) (1 trial)

propofol (diprivan) (1 trial)

sen miao san (1 trial)

umbilical cord mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Adenocarcinoma (Phase 2)

Anovulation (Phase 3)

Atrial Fibrillation (Phase 4)

Blood Coagulation Disorders (Phase 4)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 4)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 4)

Colorectal Neoplasms (Phase 2)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Digestive System Neoplasms (Phase 4)

Disseminated Intravascular Coagulation (Phase 3)

Dwarfism, Pituitary (Phase 4)

Endocrine System Diseases (Phase 4)

Eye Diseases (Phase 4)

Gallbladder Neoplasms (Phase 3)

Gastrointestinal Neoplasms (Phase 4)

Glomerulonephritis (Phase 4)

Graves Ophthalmopathy (Phase 4)

Heart Failure (Phase 3)

Heart Failure, Systolic (Phase 3)

Hemostatic Disorders (Phase 4)

Hyperphosphatemia (Phase 3)

Hypertension (Phase 4)

Hypotension (Phase 3)

IgA Vasculitis (Phase 2)

Infarction (Phase 4)

Intracranial Arteriosclerosis (Phase 2)

Intracranial Embolism (Phase 2)

Intracranial Thrombosis (Phase 2)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 3)

Leukemia (Phase 4)

Leukemia, Myeloid (Phase 4)

Leukemia, Myeloid, Acute (Phase 4)

Liver Neoplasms (Phase 4)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 2)

Lymphoma, Extranodal NK-T-Cell (Phase 2)

Lymphoma, T-Cell (Phase 2)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Myocardial Stunning (Phase 4)

Nausea (Phase 3)

Neoplasm Metastasis (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Pancreatitis (Phase 3)

Pancreatitis, Acute Necrotizing (Phase 3)

Pneumonia (Phase 3)

Purpura (Phase 3)

Purpura, Thrombocytopenic (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Rectal Neoplasms (Phase 3)

Recurrence (Phase 3)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Sarcoma (Phase 2)

Sepsis (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Stroke (Phase 4)

Syndrome (Phase 4)

Thrombocytopenia (Phase 3)

Thyroid Diseases (Phase 4)

Toxemia (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 3)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 107
  • # of Trial APIs: 134